JOURNEY MEDICAL CORPOR

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

11 Jul 2023 08:30:20 By Nasdaq GlobeNewswire

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

03 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

13 Jun 2023 08:30:59 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

22 May 2023 16:01:31 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

19 May 2023 16:01:27 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

11 May 2023 16:01:01 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

04 May 2023 09:00:26 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

29 Mar 2023 16:01:11 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

22 Mar 2023 09:00:54 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

16 Mar 2023 08:30:32 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

07 Mar 2023 08:30:31 By Nasdaq GlobeNewswire

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

20 Jan 2023 16:01:30 By Nasdaq GlobeNewswire

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

10 Jan 2023 08:30:15 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

20 Dec 2022 08:30:55 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

05 Dec 2022 16:05:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

10 Nov 2022 16:01:01 By Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

03 Nov 2022 08:52:17 By Nasdaq GlobeNewswire

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

04 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

30 Aug 2022 08:30:00 By Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

09 Aug 2022 16:01:00 By Nasdaq GlobeNewswire